In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson, with a price target of $185.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings’s rating is based on Johnson & Johnson’s strong second-quarter performance, which exceeded market expectations and demonstrated resilience despite challenges. The company reported revenue and earnings per share that surpassed consensus forecasts, indicating robust operational health. Notably, JNJ’s adjusted operational sales grew by 3.0%, overcoming a significant headwind from the loss of exclusivity on Stelara, showcasing its ability to maintain growth momentum.
Furthermore, Johnson & Johnson raised its full-year growth guidance for both adjusted operational sales and earnings per share, signaling confidence in its future prospects. The company’s strategic focus on new product launches and a promising pipeline is expected to drive accelerated growth in the latter half of 2025. This positive outlook, coupled with an improved adjusted operating margin forecast, underpins Jennings’s decision to assign a Buy rating to JNJ stock.
Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Medtronic, and Abbott Laboratories. According to TipRanks, Jennings has an average return of 2.7% and a 50.30% success rate on recommended stocks.
In another report released today, Goldman Sachs also maintained a Buy rating on the stock with a $177.00 price target.